Immunomodulation by controlling ELR+ proinflammatory chemokines levels with the long non-coding RNA UMLILO

A novel approach for detecting new anti-HIV targets that modulate HIV infection.

Contact Person

Funzani Libago



Human microRNA mimics and inhibitors that enhance and suppress HIV replication

Intellectual Property

EPO-Granted and other patents application still pending.

Technology Field

Pharmaceuticals, Biotechnology

Business Opportunity

Investment for further technology development and conduct relevant trials.

Technology Description

The present invention pertains generally to immunomodulation by altering levels of the proinflammatory chemokines. In particular, the invention relates to methods of modulating an immune response with UMLiLo, a long non-coding RNA that regulates expression of the ELR+ proinflammatory chemokines. The invention further relates to methods of treating inflammatory, autoimmune, and infectious diseases, immunodeficiency, and cancer by reducing levels of chemokines.

Benefits & Advantages

Novel mechanisms for immunomodulation by altering levels of the proinflammatory chemokines and for using same approach treating diseases that have an inflammatory related physiology


Dr Stephanie Fanucchi Dr Musa Mhlanga Youtaro Shibayama